NEW YORK (GenomeWeb) – Guardant Health announced late last week that it has signed an agreement to provide its Guardant360 liquid biopsy cancer assay to Pfizer’s oncology business unit, for use in clinical trials.
Guardant360 is a blood-based 73-gene test that investigates actionable somatic alteration across all solid tumor sites to provide clinicians with information to better manage their patients’ disease. Under the terms of the non-exclusive deal, the assay will be a Pfizer Oncology preferred circulating tumor DNA test for liquid biopsy specimens.
Additional terms of the deal were not disclosed.
Earlier this year, Guardant formed alliances with Pfizer and three other big pharma companies to develop a new 500-plus-gene liquid biopsy panel for use in clinical trials and cancer drug and immunotherapy development.